Live CME Activity Series

Evaluating
the Old and the New
in Alzheimer Disease

Instagram Live & LinkedIn Live

Register Now

cme foreground

LinkedIn Live

Alzheimer’s Disease: New Paths to Treatment

Tuesday, December 3, 2024
2:00pm EDT

Join us for a 30-minute Live CME Activity on December 3 to explore the latest insights on diagnosing, treating, and breakthroughs in Alzheimer’s Disease.

Alzheimer’s Disease (AD) is a debilitating condition marked by amyloid plaques and neurofibrillary tangles in the brain, affecting over 6 million Americans—a number expected to nearly double in the next 30 years [Alzheimer’s Association 2023]. Early detection and prevention of plaque buildup are crucial in combating the disease. Recent advances in biomarker technology are reshaping diagnosis and treatment. This session will cover key biomarkers for early screening, evaluate approved and investigational therapies, and explore methods for early-stage detection, including cognitive tests and imaging. Join us to stay at the forefront of Alzheimer’s care and research.
Supported by an educational grant from Eisai, Inc.

Instagram Live

Modernizing Today’s Alzheimer’s Treatments

Thursday, December 5, 2024
3:00pm EDT

Join a 15-minute panel on December 5 with experts discussing the latest advancements in Alzheimer’s diagnosis and treatment.

Alzheimer’s Disease is a progressive neurodegenerative disorder that profoundly impacts cognitive function, leading to memory loss, confusion, and behavioral changes. Alzheimer’s Disease affects more than 6 million Americans, a number expected to nearly double over the next 30 years [Alzheimer’s Association 2023]. The need for innovative treatments and early detection methods has never been more urgent. Join experts in the field Marc E. Agronin, MD, R. Scott Turner, PhD, MD, FANA, FAAN, and Susan Scanland, MSN, CRNP, GNP-BC, CDP, for an in-depth look at how emerging science is shaping the future of Alzheimer’s diagnosis and care.
Supported by an educational grant from Eisai, Inc.

Earn 0.5 AMA PRA Category 1 Credits™ on Dec 3 + 0.25 AMA PRA Category 1 Credits™ on Dec 5

Faculty

Marc E. Agronin, MD

Chief Medical Officer

Frank C. and Lynn Scaduto MIND Institute, Miami Jewish Health, Miami, Florida

R. Scott Turner, PhD, MD, FANA, FAAN

Professor, Department of Neurology, Director, Memory Disorders Program

Georgetown University. Washington, DC

Susan Scanland, MSN, CRNP, GNP-BC, CDP

CEO and Founder

Dementia Connection LLC, Clarks Summit, Pennsylvania

Connect with us on LinkedIn